HRT and dementia
- PMID: 10695961
HRT and dementia
Abstract
The role of HRT and/or oestrogens in the aetiology, progression and prevention of neurodegenerative disorders is unclear. Various studies have been conducted in cells, animals and humans to better define these relationships. The following is a presentation of data on the role of oestrogens in the two most common dementia syndromes Alzheimer's Disease and vascular dementia. This review examines whether there is support for the hypothesis that the use of oestrogens reduces the risk for dementia and cognitive decline in a variety of experimental models. A literature search was performed using the following key words: oestrogen and dementia, oestrogen and Alzheimer, oestrogen and cognition, oestrogen and learning, and oestrogen and memory. The reference lists for the articles identified using these search strategies were examined. The strongest evidence for a beneficial effect comes from cell and animal studies. These suggest that treatment with oestrogens may influence the pathogenetic processes of AD, mainly by affecting the beta-amyloid metabolism, by promoting the activity of the cholinergic system, by reducing oxidative stress or cardiovascular risk. Observational studies give some support to the hypothesis that HRT may be protective for cognitive decline and dementia in the elderly, but the inherited methodological problems in these studies preclude any conclusions. The treatment trials published thus far have methodological problems that prohibit definite conclusions on the relationship between HRT and cognitive decline and dementia.
Similar articles
-
[Estrogens and Alzheimer disease].Schweiz Med Wochenschr. 1999 Dec 11;129(49):1920-5. Schweiz Med Wochenschr. 1999. PMID: 10635084 Review. German.
-
[Dementia: risk and protective factors with special consideration of gender and hormone replacement therapy].Z Arztl Fortbild Qualitatssich. 2000 Apr;94(3):217-22. Z Arztl Fortbild Qualitatssich. 2000. PMID: 10802897 Review. German.
-
Can Alzheimer's or vascular dementia be prevented with control of vascular risk factors?W V Med J. 2011 May-Jun;107(3):20-5. W V Med J. 2011. PMID: 21702410 Review. No abstract available.
-
[Hormonal replacement therapy and Alzheimer's disease. All quiet on the western front?].Psychol Neuropsychiatr Vieil. 2003 Dec;1(4):251-7. Psychol Neuropsychiatr Vieil. 2003. PMID: 15683960 Review. French.
-
[Alzheimer disease, memory and estrogen].Rev Neurol (Paris). 2010 Apr;166(4):377-88. doi: 10.1016/j.neurol.2009.07.010. Rev Neurol (Paris). 2010. PMID: 19836813 Review. French.
Cited by
-
Therapeutic approaches to age-associated neurocognitive disorders.Dialogues Clin Neurosci. 2001 Sep;3(3):191-213. doi: 10.31887/DCNS.2001.3.3/rohara. Dialogues Clin Neurosci. 2001. PMID: 22033831 Free PMC article.
-
Combination pharmacotherapy in Alzheimer's disease.Dialogues Clin Neurosci. 2003 Sep;5(3):299-305. doi: 10.31887/DCNS.2003.5.3/jmintzer. Dialogues Clin Neurosci. 2003. PMID: 22033825 Free PMC article.
-
Knowledge About Alzheimer's Disease in Saudi Arabia.Cureus. 2023 Dec 8;15(12):e50188. doi: 10.7759/cureus.50188. eCollection 2023 Dec. Cureus. 2023. PMID: 38089950 Free PMC article.
-
Neuroprotective Potential of Raloxifene via G-Protein-Coupled Estrogen Receptors in Aβ-Oligomer-Induced Neuronal Injury.Biomedicines. 2023 Jul 28;11(8):2135. doi: 10.3390/biomedicines11082135. Biomedicines. 2023. PMID: 37626631 Free PMC article.
-
Estrogen and Alzheimer's disease: the story so far.Drugs Aging. 2002;19(6):405-27. doi: 10.2165/00002512-200219060-00002. Drugs Aging. 2002. PMID: 12149049 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical